Tune in to this exciting episode of BioTalk with Rich Bendis, featuring Dr. Amrie Grammer, Co-Founder of AMPEL BioSolutions. In this enlightening discussion, Dr. Grammer unveils the secrets behind AMPEL’s remarkable success in precision medicine, making this episode a must-listen.
The critical mass achieved by these collaborations provides Virginia with competitive advantages over other states and has resulted in significant outside capital being invested to finance the commercialization of Virginia’s innovations and create significant high-paying jobs for the Commonwealth.
The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2 million in grants to four life and bioscience projects in the Commonwealth of Virginia, pending execution of the grant agreements.
According to the company, the test identifies molecular markers in kidney biopsy samples of LN patients, which can help reveal patients’ disease stage. This information, in turn, could help those pharmaceutical companies who have more than 45 LN drugs in development enroll patients in clinical trials with greater precision, AMPEL said.
Suzanne Youngkin shared the goals of the W+g initiative focused on wellbeing and workforce in Virginia during her March 30th visit to AMPEL BioSolutions, a women-owned business founded,...
Different from the FM/a blood test used for diagnosis, this new blood test for Fibromyalgia may be the key to your treatment plan.